Dimensional Fund Advisors LP Decreases Holdings in Arcturus Therapeutics Holdings Inc. $ARCT

Key Points

• Dimensional Fund Advisors cut its Arcturus Therapeutics position by 41.2% in the first quarter, selling 202,074 shares and retaining 288,355 shares valued at approximately $2.23 million. Institutional investors collectively own 94.54% of ARCT.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $24.25, despite individual sell ratings from Wall Street Zen and Weiss Ratings.
• ARCT recently traded at $7.86, well below its one-year high of $24.17. The company reported a quarterly loss of $0.84 per share—better than expectations—but revenue of $2.96 million fell short of estimates.

Dimensional Fund Advisors LP lessened its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 41.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 288,355 shares of the biotechnology company's stock after selling 202,074 shares during the quarter. Dimensional Fund Advisors LP owned 1.01% of Arcturus Therapeutics worth $2,225,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC bought a new position in Arcturus Therapeutics in the 1st quarter worth $128,000. Millennium Management LLC purchased a new position in Arcturus Therapeutics during the first quarter valued at $4,892,000. Goldman Sachs Group Inc. grew its holdings in Arcturus Therapeutics by 9.1% during the first quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company's stock valued at $5,398,000 after purchasing an additional 42,636 shares during the period. Acadian Asset Management LLC bought a new stake in Arcturus Therapeutics during the first quarter valued at about $701,000. Finally, Strs Ohio purchased a new stake in Arcturus Therapeutics in the first quarter worth about $89,000. Institutional investors own 94.54% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ARCT shares. Wall Street Zen raised shares of Arcturus Therapeutics from a "strong sell" rating to a "sell" rating in a report on Sunday, August 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $24.25.

Arcturus Therapeutics Price Performance

NASDAQ ARCT opened at $7.86 on Friday. The stock has a market capitalization of $223.38 million, a PE ratio of -2.37 and a beta of 2.39. The business has a 50 day simple moving average of $6.75 and a two-hundred day simple moving average of $7.39. Arcturus Therapeutics Holdings Inc. has a 1-year low of $5.50 and a 1-year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.84) EPS for the quarter, beating analysts' consensus estimates of ($1.00) by $0.16. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. The firm had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. On average, analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -3.48 EPS for the current fiscal year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus's approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company's pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.

Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source